Medios expects further growth in revenue and earnings after record year 2024
|
EQS-News: Medios AG
/ Key word(s): Annual Results/Annual Report
Press release Medios expects further growth in revenue and earnings after record year 2024
Berlin, March 25, 2025 – The Medios Group ("Medios"), a leading provider of Specialty Pharma in Europe, has once again achieved record results in the 2024 financial year. Consolidated revenue increased by 5.5% year on year to €1.9 billion (previous year: €1.8 billion). EBITDA pre1 rose significantly by 30.5% to €79 million (previous year: €60.5 million). The EBITDA pre1 margin improved significantly to 4.2% (previous year: 3.4%). The disproportionate increase in EBITDA pre1 is due in particular to the acquisition of the Ceban Group and the associated internationalization. In addition, the operating cash flow reached an exceptionally high level of €73.7 million, reflecting the positive development of the operating result and a reduction in net working capital as of the reporting date. The audited results for 2024 are thus in line with the adjusted forecast of December 12, 2024 and confirm the preliminary figures published on March 4, 2025. Matthias Gaertner, CEO of Medios AG: “We have significantly and sustainably increased our profitability in 2024. At the same time, we have consistently driven forward the development of our European Specialty Pharma platform and further expanded our business in the field of Advanced Therapies. The exceptionally high operating cash flow is proof of our company's financial strength. We will continue on this positive development in 2025 and push ahead with our profitable growth. We expect to see a further significant increase in the EBITDA pre¹ margin to around 4.8%.” All operating segments contributed to increase in earnings In the Pharmaceutical Supply segment, external revenue rose to €1,580.0 million in the 2024 financial year (previous year: €1,558.1 million), which corresponds to a slight growth of 1.4% compared to the previous year. EBITDA pre1 increased disproportionately by 7.2% to €50.0 million (previous year: €46.7 million). The Patient-Specific Therapies segment generated external revenue of €213.6 million (previous year: €226.0 million), a slight decline of 5.5%. By contrast, EBITDA pre1 increased by 6.6% to €23.3 million (previous year: €21.8 million), thanks in particular to strong growth in the second half of 2024. The increases in earnings in the segments of Pharmaceutical Supply and Patient-Specific Therapies were achieved exclusively organically. The International Business segment comprises the activities of Ceban Pharmaceuticals B.V. (“Ceban”), which has been included in the scope of consolidation since June 1, 2024. The segment contributed significantly to the positive development of the Medios Group in the 2024 financial year, with external revenue of €88.8 million and EBITDA pre1 of €16.3 million. Positive outlook for the 2025 financial year For the 2025 financial year, the Medios Group expects an increase in revenue of around 6% to around €2 billion. EBITDA pre1 is expected to increase disproportionately by around 21.5% to around €96 million. This corresponds to a further increase in the EBITDA pre1 margin to around 4.8%. This expectation is based on the assumption of organic growth in the mid-single-digit percentage range and takes into account the consolidation of the Ceban Group for twelve months.
Important dates for Medios Group in the 2025 financial year:
1 EBITDA is defined as consolidated earnings before interest, taxes, depreciation and amortization. EBITDA pre is adjusted for special charges for stock options, expenses for M&A activities and for 2023 and 2024 for performance-based payments for the acquisition of compounding volumes as well as from 2024 expenses for ERP-System implementation. ------------------- About Medios AG Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies. Medios AG is Germany's first listed specialty pharmaceutical company. The shares are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index. Contact Claudia Nickolaus This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.
25.03.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | Medios AG |
| Heidestraße 9 | |
| 10557 Berlin | |
| Germany | |
| Phone: | +49 30 232 566 - 800 |
| Fax: | +49 30 232 566 - 801 |
| E-mail: | ir@medios.ag |
| Internet: | www.medios.ag |
| ISIN: | DE000A1MMCC8 |
| WKN: | A1MMCC |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2105292 |
| End of News | EQS News Service |
|
|
2105292 25.03.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.